BET bromodomains' functions in bone-related pathologies

Bone remodeling is a lifelong process governed by osteoblasts and osteoclasts. This balance is essential for maintaining skeletal integrity. Disruptions in this process lead to pathologies like osteoporosis or bone sarcomas. These conditions often lack targetable genetic mutations, limiting treatment options. Epigenetic strategies have emerged as potential therapeutic avenues. Bromodomain and extraterminal (BET) proteins are epigenetic regulators with roles in various diseases. Their involvement in bone biology is a recent focus of research. Prior studies have shown BET proteins influence gene expression in cancer. However, their specific roles in bone-related diseases remain unclear.

This review aims to examine the role of BET bromodomain proteins in bone biology and pathology. It seeks to clarify how these proteins influence bone remodeling and related diseases. The study addresses a gap in understanding BET proteins' functions in skeletal disorders. Researchers aim to synthesize existing evidence on BET proteins in bone health. The goal is to determine if these proteins are viable therapeutic targets. The authors propose to analyze current findings on BET proteins in bone sarcomas. This work may guide future investigations into epigenetic therapies. The review focuses on primary bone sarcomas and metabolic bone diseases.

The authors conducted a literature review of BET bromodomain functions in bone biology. They synthesized findings from studies on bone remodeling and sarcomas. The review approach included analyzing BET proteins' roles in osteoblast and osteoclast activity. Researchers evaluated how BET proteins regulate gene expression in bone cells. The study also examined the implications of BET inhibition in sarcoma models. The authors compared findings from metabolic and malignant bone diseases. They focused on studies that directly link BET proteins to bone defects. The review approach highlights gaps and inconsistencies in current research.

BET proteins influence osteoblast and osteoclast differentiation and activity. Inhibiting BET proteins reduces osteoclast formation in sarcoma models. These proteins regulate genes involved in bone matrix production and resorption. BET inhibition may suppress tumor growth in primary bone sarcomas. The review suggests BET proteins modulate inflammatory pathways in bone. Their role in osteoporosis remains less clear, with conflicting evidence. Some studies show BET inhibition improves bone density in animal models. However, other findings suggest BET proteins may protect against bone loss.

The authors propose that BET proteins are involved in both normal and pathological bone remodeling. Their findings suggest BET inhibition could be a therapeutic strategy for bone sarcomas. The review highlights the need for further studies on BET proteins in metabolic bone diseases. The authors emphasize that current evidence is preliminary and requires validation. They suggest BET proteins may serve as biomarkers for bone-related pathologies. The review concludes that BET proteins are promising but not yet fully characterized targets. The authors recommend exploring BET inhibitors in clinical trials for bone sarcomas. They caution that more research is needed to clarify BET proteins' roles in different bone conditions.